Cargando…

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate

BACKGROUND: In clinical practice, α(2)-adrenoceptor agonists have been adjunctively administered with psychostimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD). Two studies have examined the adjunctive use of guanfacine extended release (GXR, Intuniv(®); Shire Development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roesch, Benno, Corcoran, Mary E., Fetterolf, Jennifer, Haffey, Mary, Martin, Patrick, Preston, Peter, Purkayastha, Jaideep, Wang, Phillip, Ermer, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing AG 2013
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689918/ https://www.ncbi.nlm.nih.gov/pubmed/23615868 http://dx.doi.org/10.1007/s40268-013-0014-8

Ejemplares similares

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults
por: Ermer, James, et al.
Publicado: (2013)

Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults
por: Ermer, James, et al.
Publicado: (2013)

Relative Bioavailabilities of Lisdexamfetamine Dimesylate and d-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink
por: Ermer, James, et al.
Publicado: (2016)

Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study
por: Ermer, James, et al.
Publicado: (2015)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
por: Ermer, James C., et al.
Publicado: (2016)

A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
por: Ermer, James, et al.
Publicado: (2019)

A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
por: Coghill, David R., et al.
Publicado: (2014)

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
por: Pennick, Michael
Publicado: (2010)

Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
por: Najib, Jadwiga, et al.
Publicado: (2017)

Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2020)

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
por: Adler, Lenard A, et al.
Publicado: (2009)

The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA
por: Ágh, Tamás, et al.
Publicado: (2016)

Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder
por: Griffiths, Kristi R., et al.
Publicado: (2021)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2020)

Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the Effects of Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts on Cognition Throughout the Day in Adults with Attention-Deficit/Hyperactivity Disorder
por: Martin, Patrick T., et al.
Publicado: (2013)

Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges
por: López, Frank A., et al.
Publicado: (2013)

Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use
por: Jain, Rakesh, et al.
Publicado: (2013)

Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
por: Ichikawa, Hironobu, et al.
Publicado: (2019)

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe
por: Siffel, Csaba, et al.
Publicado: (2020)

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
por: Joseph, Alain, et al.
Publicado: (2016)

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
por: Zimovetz, Evelina A., et al.
Publicado: (2017)

Identification, Characterization and Quantification of Process-Related and Degradation Impurities in Lisdexamfetamine Dimesylate: Identifiction of Two New Compounds
por: Gao, Shenghua, et al.
Publicado: (2018)

Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
por: Ichikawa, Hironobu, et al.
Publicado: (2020)

Influence of Lisdexamfetamine Dimesylate on Early Ejaculation—Results from a Double-Blind Randomized Clinical Trial
por: Haghighi, Mohammad, et al.
Publicado: (2021)

Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa
por: Dixon, Laura, et al.
Publicado: (2023)

Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended‐release tablets
por: Inoue, Yuji, et al.
Publicado: (2019)

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents
por: Bello, Nicholas T
Publicado: (2015)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donors*
por: Pennick, Michael
Publicado: (2013)

Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol
por: Griffiths, Kristi R., et al.
Publicado: (2019)

Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale
por: Yee, Karen S., et al.
Publicado: (2020)

Traumatic Brain Injury-Related Attention Deficits in Children: A Controlled Treatment Trial with Lisdexamfetamine Dimesylate (Vyvanse)
por: Tramontana, Michael G., et al.
Publicado: (2021)

Correction: Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa
por: Dixon, Laura, et al.
Publicado: (2023)

A Post Hoc Comparison of the Effects of Lisdexamfetamine Dimesylate and Osmotic-Release Oral System Methylphenidate on Symptoms of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Soutullo, César, et al.
Publicado: (2013)

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder
por: Wigal, Sharon B, et al.
Publicado: (2009)

Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis
por: Jain, Rakesh, et al.
Publicado: (2011)

Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
por: Mattingly, Greg W, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9gj2dnt9mprj3ro4cigqs50a74